Data on these substances are still limited to animal models and early-phase human studies; however, an initial trial using 89Zr-atezolizumab for PET imaging showed very promising results assessing clinical response to PD-L1 blockade in 25 patients with locally advanced or metastatic bladder cancer, non-small-cell lung cancer (NSCLC) or triple-negative breast cancer. The gene discussed is CD274; the disease is non-small cell lung carcinoma.